Matching Items (2)
Filtering by

Clear all filters

136665-Thumbnail Image.png

Confessions of a College Entrepreneur

Description
The Confessions of a College Entrepreneur is an honors project with the goal of revealing the business and marketing strategies that Charles Crawford used to create multiple successful companies. It's a collection of personal stories, book notes, millionaire interviews, and experiences that Charles had over the past 4 years of…

The Confessions of a College Entrepreneur is an honors project with the goal of revealing the business and marketing strategies that Charles Crawford used to create multiple successful companies. It's a collection of personal stories, book notes, millionaire interviews, and experiences that Charles had over the past 4 years of intense business experience and research across multiple industries. Charles wants college students and business owners to succeed in business ventures and life in general. This creative thesis project is the map for how to do just that.
ContributorsCrawford, Charles Joseph (Author) / Budolfson, Arthur (Thesis director) / Giles, Charles (Committee member) / Barrett, The Honors College (Contributor) / Department of Finance (Contributor)
Created2014-12
134601-Thumbnail Image.png

Avastin: Roche Pharmaceutical's Cancer Treatment & The United States Healthcare System

Description
This paper seeks to put a spotlight on much that is wrong in the United States with cancer drug development, pricing, marketing and outcomes. Roche Pharmaceutical's cancer drug, Avastin will be used as an example to highlight these issues. Drug patents, Medicare policies, weak metrics of efficacy and ceaseless demand—allow…

This paper seeks to put a spotlight on much that is wrong in the United States with cancer drug development, pricing, marketing and outcomes. Roche Pharmaceutical's cancer drug, Avastin will be used as an example to highlight these issues. Drug patents, Medicare policies, weak metrics of efficacy and ceaseless demand—allow drug manufacturers to price their oncology treatments as they choose, regardless of results, and with virtually no competition, avenue or institution that serves to lower prices in the United States. Avastin will be established as an oncology drug that is overpriced and poorly evaluated based on its effectiveness. Facts, opinions and study analytics will be offered (from industry experts, insiders, doctors and scientists) that in almost all cases show that patients treated with Avastin receive marginal benefit. Allowing Medicare to negotiate drug prices with manufacturers, reducing conflicts of interest for doctors, setting research & development investment requirements and creating more relevant clinical metrics for use in FDA approvals would help reduce the financial burden on cancer patients and taxpayers.
ContributorsTrettin, Michael William (Author) / Simonson, Mark (Thesis director) / Budolfson, Arthur (Committee member) / Department of Finance (Contributor) / Barrett, The Honors College (Contributor)
Created2017-05